Active 0 6 0 6 B-chronic_disease
hepatitis 7 16 7 16 I-chronic_disease
B 17 18 17 18 I-chronic_disease
or 19 21 19 21 I-chronic_disease
C 22 23 22 23 I-chronic_disease
viral 24 29 24 29 B-chronic_disease
infection 30 39 30 39 I-chronic_disease
or 40 42 40 42 O
hepatitis 43 52 43 52 B-chronic_disease
B 53 54 53 54 I-chronic_disease
surface 55 62 55 62 I-chronic_disease
antigen 63 70 63 70 I-chronic_disease
positive 71 79 71 79 O

Any 0 3 80 83 O
cytogenetic 4 15 84 95 B-cancer
abnormality 16 27 96 107 I-cancer
in 28 30 108 110 I-cancer
the 31 34 111 114 I-cancer
bone 35 39 115 119 I-cancer
marrow 40 46 120 126 I-cancer
that 47 51 127 131 O
is 52 54 132 134 O
known 55 60 135 140 O
to 61 63 141 143 O
be 64 66 144 146 O
associated 67 77 147 157 O
with 78 82 158 162 O
or 83 85 163 165 O
predictive 86 96 166 176 O
of 97 99 177 179 O
myelodysplasia 100 114 180 194 B-cancer
is 115 117 195 197 O
excluded 118 126 198 206 O

Bilirubin 0 9 207 216 B-clinical_variable
< 10 11 217 218 O
1.5 12 15 219 222 B-upper_bound
x 16 17 223 224 I-upper_bound
normal 18 24 225 231 I-upper_bound
except 25 31 232 238 O
in 32 34 239 241 O
cases 35 40 242 247 O
where 41 46 248 253 O
abnormal 47 55 254 262 O
liver 56 61 263 268 O
function 62 70 269 277 O
tests 71 76 278 283 O
( 77 78 284 285 O
LFTS 78 82 285 289 O
) 82 83 289 290 O
are 84 87 291 294 O
due 88 91 295 298 O
to 92 94 299 301 O
involvement 95 106 302 313 O
with 107 111 314 318 O
T 112 113 319 320 O
- 113 114 320 321 O
NHL 114 117 321 324 O

Body 0 4 325 329 B-bmi
mass 5 9 330 334 I-bmi
index 10 15 335 340 I-bmi
( 16 17 341 342 I-bmi
BMI 17 20 342 345 I-bmi
) 20 21 345 346 I-bmi
> 22 23 347 348 O
35 24 26 349 351 B-lower_bound
% 26 27 351 352 I-lower_bound
will 28 32 353 357 O
be 33 35 358 360 O
considered 36 46 361 371 O
on 47 49 372 374 O
a 50 51 375 376 O
case 52 56 377 381 O
- 56 57 381 382 O
by 57 59 382 384 O
- 59 60 384 385 O
case 60 64 385 389 O
basis 65 70 390 395 O
by 71 73 396 398 O
the 74 77 399 402 O
Radiation 78 87 403 412 O
Oncology 88 96 413 421 O
principal 97 106 422 431 O
investigator 107 119 432 444 O
( 120 121 445 446 O
P.I. 121 125 446 450 O
) 125 126 450 451 O

Bone 0 4 452 456 O
marrow 5 11 457 463 O
( 12 13 464 465 O
BM 13 15 465 467 O
) 15 16 467 468 O
harvest 17 24 469 476 O
required 25 33 477 485 O
to 34 36 486 488 O
reach 37 42 489 494 O
adequate 43 51 495 503 O
cell 52 56 504 508 O
dose 57 61 509 513 O
for 62 65 514 517 O
transplant 66 76 518 528 B-treatment

Cardiac 0 7 529 536 B-clinical_variable
ejection 8 16 537 545 I-clinical_variable
fraction 17 25 546 554 I-clinical_variable
of 26 28 555 557 O
> 29 30 558 559 O
= 30 31 559 560 O
50 32 34 561 563 B-lower_bound
% 34 35 563 564 I-lower_bound
by 36 38 565 567 O
echocardiogram 39 53 568 582 B-treatment
or 54 56 583 585 O
multi 57 62 586 591 B-treatment
gated 63 68 592 597 I-treatment
acquisition 69 80 598 609 I-treatment
scan 81 85 610 614 I-treatment
( 86 87 615 616 I-treatment
MUGA 87 91 616 620 I-treatment
) 91 92 620 621 I-treatment

Evidence 0 8 622 630 O
of 9 11 631 633 O
marrow 12 18 634 640 O
disease 19 26 641 648 O
by 27 29 649 651 O
flow 30 34 652 656 O
and 35 38 657 660 O
morphology 39 49 661 671 O
after 50 55 672 677 O
upfront 56 63 678 685 O
or 64 66 686 688 O
salvage 67 74 689 696 B-treatment
cytoreductive 75 88 697 710 I-treatment
therapy 89 96 711 718 I-treatment
and 97 100 719 722 O
before 101 107 723 729 O
stem 108 112 730 734 B-treatment
cell 113 117 735 739 I-treatment
mobilization 118 130 740 752 I-treatment

First 0 5 753 758 O
remission 6 15 759 768 O
after 16 21 769 774 O
initial 22 29 775 782 O
first 30 35 783 788 B-treatment
- 35 36 788 789 I-treatment
line 36 40 789 793 I-treatment
therapy 41 48 794 801 I-treatment
( 49 50 802 803 O
CR1 50 53 803 806 O
) 53 54 806 807 O
in 55 57 808 810 O
PTCL 58 62 811 815 B-cancer
patients 63 71 816 824 O
, 71 72 824 825 O
except 73 79 826 832 O
for 80 83 833 836 O
anaplastic 84 94 837 847 O
lymphoma 95 103 848 856 O
receptor 104 112 857 865 O
tyrosine 113 121 866 874 O
kinase 122 128 875 881 O
( 129 130 882 883 O
ALK)+ 130 135 883 888 O
anaplastic 136 146 889 899 B-cancer
large 147 152 900 905 I-cancer
cell 153 157 906 910 I-cancer
lymphoma 158 166 911 919 I-cancer
( 167 168 920 921 I-cancer
ALCL 168 172 921 925 I-cancer
) 172 173 925 926 I-cancer
and 174 177 927 930 O
CTCL 178 182 931 935 B-cancer

Forced 0 6 936 942 B-clinical_variable
expiratory 7 17 943 953 I-clinical_variable
volume 18 24 954 960 I-clinical_variable
in 25 27 961 963 I-clinical_variable
one 28 31 964 967 I-clinical_variable
second 32 38 968 974 I-clinical_variable
( 39 40 975 976 I-clinical_variable
FEV1 40 44 976 980 I-clinical_variable
) 44 45 980 981 I-clinical_variable
> 46 47 982 983 O
65 48 50 984 986 B-lower_bound
% 50 51 986 987 I-lower_bound
of 52 54 988 990 I-lower_bound
predicted 55 64 991 1000 I-lower_bound
measured 65 73 1001 1009 I-lower_bound
, 73 74 1009 1010 O
or 75 77 1011 1013 O
diffusing 78 87 1014 1023 B-lower_bound
capacity 88 96 1024 1032 I-lower_bound
of 97 99 1033 1035 I-lower_bound
the 100 103 1036 1039 I-lower_bound
lung 104 108 1040 1044 I-lower_bound
for 109 112 1045 1048 I-lower_bound
carbon 113 119 1049 1055 I-lower_bound
monoxide 120 128 1056 1064 I-lower_bound
( 129 130 1065 1066 I-lower_bound
DLCO 130 134 1066 1070 I-lower_bound
) 134 135 1070 1071 I-lower_bound
> 136 137 1072 1073 O
50 138 140 1074 1076 B-lower_bound
% 140 141 1076 1077 I-lower_bound
of 142 144 1078 1080 I-lower_bound
predicted 145 154 1081 1090 I-lower_bound
measured 155 163 1091 1099 I-lower_bound

History 0 7 1100 1107 O
of 8 10 1108 1110 O
allergic 11 19 1111 1119 O
reactions 20 29 1120 1129 O
attributed 30 40 1130 1140 O
to 41 43 1141 1143 O
compounds 44 53 1144 1153 B-allergy_name
of 54 56 1154 1156 I-allergy_name
similar 57 64 1157 1164 I-allergy_name
chemical 65 73 1165 1173 I-allergy_name
or 74 76 1174 1176 I-allergy_name
biologic 77 85 1177 1185 I-allergy_name
composition 86 97 1186 1197 I-allergy_name
to 98 100 1198 1200 I-allergy_name
basiliximab 101 112 1201 1212 I-allergy_name

Karnofsky 0 9 1213 1222 B-clinical_variable
status 10 16 1223 1229 I-clinical_variable
> 17 18 1230 1231 O
= 18 19 1231 1232 O
70 20 22 1233 1235 B-lower_bound
% 22 23 1235 1236 I-lower_bound

Life 0 4 1237 1241 B-clinical_variable
expectancy 5 15 1242 1252 I-clinical_variable
> 16 17 1253 1254 O
= 17 18 1254 1255 O
6 19 20 1256 1257 B-lower_bound
months 21 27 1258 1264 I-lower_bound

Pregnant 0 8 1265 1273 B-pregnancy
women 9 14 1274 1279 B-gender

Presence 0 8 1280 1288 O
of 9 11 1289 1291 O
antibody 12 20 1292 1300 O
against 21 28 1301 1308 O
basiliximab 29 40 1309 1320 B-treatment
in 41 43 1321 1323 O
serum 44 49 1324 1329 O
( 50 51 1330 1331 O
only 51 55 1331 1335 O
required 56 64 1336 1344 O
for 65 68 1345 1348 O
patients 69 77 1349 1357 O
who 78 81 1358 1361 O
have 82 86 1362 1366 O
received 87 95 1367 1375 O
prior 96 101 1376 1381 O
antibody 102 110 1382 1390 O
) 110 111 1390 1391 O

Prior 0 5 1392 1397 O
high 6 10 1398 1402 O
dose 11 15 1403 1407 O
chemotherapy 16 28 1408 1420 B-treatment
for 29 32 1421 1424 O
autologous 33 43 1425 1435 B-treatment
hematopoietic 44 57 1436 1449 I-treatment
cell 58 62 1450 1454 I-treatment
transplantation 63 78 1455 1470 I-treatment
or 79 81 1471 1473 O
prior 82 87 1474 1479 B-treatment
allogeneic 88 98 1480 1490 I-treatment
transplantation 99 114 1491 1506 I-treatment

Progressive 0 11 1507 1518 B-chronic_disease
disease 12 19 1519 1526 I-chronic_disease

Recovery 0 8 1527 1535 O
from 9 13 1536 1540 O
non 14 17 1541 1544 O
- 17 18 1544 1545 O
hematologic 18 29 1545 1556 O
toxicities 30 40 1557 1567 O
of 41 43 1568 1570 O
salvage 44 51 1571 1578 B-treatment
cytoreductive 52 65 1579 1592 I-treatment
chemotherapy 66 78 1593 1605 I-treatment
to 79 81 1606 1608 O
= 82 83 1609 1610 O
< 83 84 1610 1611 O
grade 85 90 1612 1617 B-upper_bound
2 91 92 1618 1619 I-upper_bound
( 93 94 1620 1621 O
Common 94 100 1621 1627 B-clinical_variable
Terminology 101 112 1628 1639 I-clinical_variable
Criteria 113 121 1640 1648 I-clinical_variable
for 122 125 1649 1652 I-clinical_variable
Adverse 126 133 1653 1660 I-clinical_variable
Events 134 140 1661 1667 I-clinical_variable
[ 141 142 1668 1669 I-clinical_variable
CTCAE 142 147 1669 1674 I-clinical_variable
] 147 148 1674 1675 I-clinical_variable
version 149 156 1676 1683 I-clinical_variable
4 157 158 1684 1685 I-clinical_variable
[ 159 160 1686 1687 O
v4 160 162 1687 1689 O
] 162 163 1689 1690 O
) 163 164 1690 1691 O

Relapsed 0 8 1692 1700 O
/ 8 9 1700 1701 O
refractory 9 19 1701 1711 O
disease 20 27 1712 1719 O
, 27 28 1719 1720 O
stable 29 35 1721 1727 O
disease 36 43 1728 1735 O
, 43 44 1735 1736 O
partial 45 52 1737 1744 O
remission 53 62 1745 1754 O
( 63 64 1755 1756 O
PR 64 66 1756 1758 O
) 66 67 1758 1759 O
or 68 70 1760 1762 O
complete 71 79 1763 1771 O
remission 80 89 1772 1781 O
( 90 91 1782 1783 O
CR 91 93 1783 1785 O
) 93 94 1785 1786 O
, 94 95 1786 1787 O
who 96 99 1788 1791 O
have 100 104 1792 1796 O
received 105 113 1797 1805 O
at 114 116 1806 1808 O
least 117 122 1809 1814 O
2 123 124 1815 1816 B-lower_bound
lines 125 130 1817 1822 I-lower_bound
of 131 133 1823 1825 O
therapy 134 141 1826 1833 B-treatment
, 141 142 1833 1834 O
and 143 146 1835 1838 O
do 147 149 1839 1841 O
not 150 153 1842 1845 O
have 154 158 1846 1850 O
an 159 161 1851 1853 O
adequate 162 170 1854 1862 O
allogenetic 171 182 1863 1874 B-treatment
stem 183 187 1875 1879 I-treatment
cell 188 192 1880 1884 I-treatment
transplant 193 203 1885 1895 I-treatment
option 204 210 1896 1902 O

Research 0 8 1903 1911 O
participants 9 21 1912 1924 O
with 22 26 1925 1929 O
presence 27 35 1930 1938 O
of 36 38 1939 1941 O
other 39 44 1942 1947 O
active 45 51 1948 1954 O
malignancy 52 62 1955 1965 B-cancer

Serum 0 5 1966 1971 B-clinical_variable
creatinine 6 16 1972 1982 I-clinical_variable
of 17 19 1983 1985 O
< 20 21 1986 1987 O
1.5 22 25 1988 1991 B-upper_bound
mg 26 28 1992 1994 I-upper_bound
/ 28 29 1994 1995 I-upper_bound
dL 29 31 1995 1997 I-upper_bound
, 31 32 1997 1998 O
and 33 36 1999 2002 O
a 37 38 2003 2004 O
measured 39 47 2005 2013 B-clinical_variable
creatinine 48 58 2014 2024 I-clinical_variable
clearance 59 68 2025 2034 I-clinical_variable
of 69 71 2035 2037 O
> 72 73 2038 2039 O
60 74 76 2040 2042 B-lower_bound
mL 77 79 2043 2045 I-lower_bound
/ 79 80 2045 2046 I-lower_bound
min 80 83 2046 2049 I-lower_bound

Serum 0 5 2050 2055 B-clinical_variable
glutamic 6 14 2056 2064 I-clinical_variable
oxaloacetic 15 26 2065 2076 I-clinical_variable
transaminase 27 39 2077 2089 I-clinical_variable
( 40 41 2090 2091 I-clinical_variable
SGOT 41 45 2091 2095 I-clinical_variable
) 45 46 2095 2096 I-clinical_variable
AND 47 50 2097 2100 O
serum 51 56 2101 2106 B-clinical_variable
glutamate 57 66 2107 2116 I-clinical_variable
pyruvate 67 75 2117 2125 I-clinical_variable
transaminase 76 88 2126 2138 I-clinical_variable
( 89 90 2139 2140 I-clinical_variable
SGPT 90 94 2140 2144 I-clinical_variable
) 94 95 2144 2145 I-clinical_variable
< 96 97 2146 2147 O
2 98 99 2148 2149 B-upper_bound
x 100 101 2150 2151 I-upper_bound
normal 102 108 2152 2158 I-upper_bound
except 109 115 2159 2165 O
in 116 118 2166 2168 O
cases 119 124 2169 2174 O
where 125 130 2175 2180 O
abnormal 131 139 2181 2189 O
LFTS 140 144 2190 2194 O
are 145 148 2195 2198 O
due 149 152 2199 2202 O
to 153 155 2203 2205 O
involvement 156 167 2206 2217 O
with 168 172 2218 2222 O
T 173 174 2223 2224 B-cancer
- 174 175 2224 2225 I-cancer
NHL 175 178 2225 2228 I-cancer

Significant 0 11 2229 2240 O
prior 12 17 2241 2246 B-treatment
external 18 26 2247 2255 I-treatment
beam 27 31 2256 2260 I-treatment
dose 32 36 2261 2265 I-treatment
- 36 37 2265 2266 I-treatment
limiting 37 45 2266 2274 I-treatment
radiation 46 55 2275 2284 I-treatment
to 56 58 2285 2287 O
a 59 60 2288 2289 O
critical 61 69 2290 2298 O
organ 70 75 2299 2304 O
based 76 81 2305 2310 O
on 82 84 2311 2313 O
review 85 91 2314 2320 O
of 92 94 2321 2323 O
the 95 98 2324 2327 O
prior 99 104 2328 2333 B-treatment
radiation 105 114 2334 2343 I-treatment
treatment 115 124 2344 2353 I-treatment
records 125 132 2354 2361 O
by 133 135 2362 2364 O
the 136 139 2365 2368 O
Radiation 140 149 2369 2378 O
Oncology 150 158 2379 2387 O
PI 159 161 2388 2390 O
; 161 162 2390 2391 O
patients 163 171 2392 2400 O
who 172 175 2401 2404 O
have 176 180 2405 2409 O
had 181 184 2410 2413 O
prior 185 190 2414 2419 O
external 191 199 2420 2428 B-treatment
beam 200 204 2429 2433 I-treatment
radiation 205 214 2434 2443 I-treatment
> 215 216 2444 2445 O
2000 217 221 2446 2450 B-lower_bound
cGy 222 225 2451 2454 I-lower_bound
( 226 227 2455 2456 O
at 227 229 2456 2458 O
180 230 233 2459 2462 B-lower_bound
to 234 236 2463 2465 O
200 237 240 2466 2469 B-upper_bound
cGy 241 244 2470 2473 I-upper_bound
per 245 248 2474 2477 O
day 249 252 2478 2481 O
) 252 253 2481 2482 O
to 254 256 2483 2485 O
the 257 260 2486 2489 O
lung 261 265 2490 2494 O
will 266 270 2495 2499 O
be 271 273 2500 2502 O
ineligible 274 284 2503 2513 O

Systemic 0 8 2514 2522 B-treatment
chemotherapy 9 21 2523 2535 I-treatment
or 22 24 2536 2538 O
radiation 25 34 2539 2548 B-treatment
can 35 38 2549 2552 O
not 38 41 2552 2555 O
have 42 46 2556 2560 O
been 47 51 2561 2565 O
given 52 57 2566 2571 O
within 58 64 2572 2578 O
4 65 66 2579 2580 B-upper_bound
weeks 67 72 2581 2586 I-upper_bound
prior 73 78 2587 2592 I-upper_bound
to 79 81 2593 2595 O
the 82 85 2596 2599 O
Y-90 86 90 2600 2604 B-treatment
dose 91 95 2605 2609 O
of 96 98 2610 2612 O
radioimmunotherapy 99 117 2613 2631 B-treatment
( 118 119 2632 2633 I-treatment
RIT 119 122 2633 2636 I-treatment
) 122 123 2636 2637 I-treatment
, 123 124 2637 2638 O
with 125 129 2639 2643 O
the 130 133 2644 2647 O
exception 134 143 2648 2657 O
of 144 146 2658 2660 O
single 147 153 2661 2667 B-treatment
agent 154 159 2668 2673 I-treatment
cyclophosphamide 160 176 2674 2690 I-treatment
priming 177 184 2691 2698 O
chemotherapy 185 197 2699 2711 O
administered 198 210 2712 2724 O
for 211 214 2725 2728 O
mobilization 215 227 2729 2741 O

T 0 1 2742 2743 B-cancer
- 1 2 2743 2744 I-cancer
NHL 2 5 2744 2747 I-cancer
histologies 6 17 2748 2759 O
including 18 27 2760 2769 O
peripheral 28 38 2770 2780 B-cancer
T 39 40 2781 2782 I-cancer
- 40 41 2782 2783 I-cancer
cell 41 45 2783 2787 I-cancer
lymphomas 46 55 2788 2797 I-cancer
( 56 57 2798 2799 I-cancer
PTCLs 57 62 2799 2804 I-cancer
) 62 63 2804 2805 I-cancer
, 63 64 2805 2806 O
cutaneous 65 74 2807 2816 B-cancer
T 75 76 2817 2818 I-cancer
- 76 77 2818 2819 I-cancer
cell 77 81 2819 2823 I-cancer
lymphomas 82 91 2824 2833 I-cancer
( 92 93 2834 2835 I-cancer
CTCLs 93 98 2835 2840 I-cancer
) 98 99 2840 2841 I-cancer
and 100 103 2842 2845 O
natural 104 111 2846 2853 B-cancer
killer 112 118 2854 2860 I-cancer
( 119 120 2861 2862 I-cancer
NK)/T 120 125 2862 2867 I-cancer
cell 126 130 2868 2872 I-cancer
lymphomas 131 140 2873 2882 I-cancer

Women 0 5 2883 2888 B-gender
of 6 8 2889 2891 O
child 9 14 2892 2897 O
- 14 15 2897 2898 O
bearing 15 22 2898 2905 O
potential 23 32 2906 2915 O
and 33 36 2916 2919 O
men 37 40 2920 2923 O
must 41 45 2924 2928 O
agree 46 51 2929 2934 B-contraception_consent
to 52 54 2935 2937 I-contraception_consent
use 55 58 2938 2941 I-contraception_consent
adequate 59 67 2942 2950 I-contraception_consent
contraception 68 81 2951 2964 I-contraception_consent
( 82 83 2965 2966 O
hormonal 83 91 2966 2974 B-contraception_consent
or 92 94 2975 2977 I-contraception_consent
barrier 95 102 2978 2985 I-contraception_consent
method 103 109 2986 2992 I-contraception_consent
of 110 112 2993 2995 I-contraception_consent
birth 113 118 2996 3001 I-contraception_consent
control 119 126 3002 3009 I-contraception_consent
or 127 129 3010 3012 O
abstinence 130 140 3013 3023 B-contraception_consent
) 140 141 3023 3024 O
prior 142 147 3025 3030 O
to 148 150 3031 3033 O
study 151 156 3034 3039 O
entry 157 162 3040 3045 O
and 163 166 3046 3049 O
for 167 170 3050 3053 O
six 171 174 3054 3057 B-upper_bound
months 175 181 3058 3064 I-upper_bound
following 182 191 3065 3074 O
duration 192 200 3075 3083 O
of 201 203 3084 3086 O
study 204 209 3087 3092 O
participation 210 223 3093 3106 O

breastfeeding 0 13 3107 3120 O
should 14 20 3121 3127 O
be 21 23 3128 3130 O
discontinued 24 36 3131 3143 O
if 37 39 3144 3146 O
the 40 43 3147 3150 O
mother 44 50 3151 3157 O
is 51 53 3158 3160 O
treated 54 61 3161 3168 O
with 62 66 3169 3173 O
indium 67 73 3174 3180 B-treatment
In 74 76 3181 3183 I-treatment
111 77 80 3184 3187 I-treatment
( 81 82 3188 3189 I-treatment
111In- 82 88 3189 3195 I-treatment
) 88 89 3195 3196 I-treatment
and 90 93 3197 3200 O
90Y 94 97 3201 3204 B-treatment
- 97 98 3204 3205 I-treatment
basiliximab 98 109 3205 3216 I-treatment
- 109 110 3216 3217 I-treatment
DOTA 110 114 3217 3221 I-treatment

detectable 0 10 3222 3232 O
human 11 16 3233 3238 B-chronic_disease
immunodeficiency 17 33 3239 3255 I-chronic_disease
virus 34 39 3256 3261 I-chronic_disease
( 40 41 3262 3263 I-chronic_disease
HIV 41 44 3263 3266 I-chronic_disease
) 44 45 3266 3267 I-chronic_disease
viral 46 51 3268 3273 O
load 52 56 3274 3278 O
or 57 59 3279 3281 O
who 60 63 3282 3285 O
are 64 67 3286 3289 O
HIV 68 71 3290 3293 O
- 71 72 3293 3294 O
positive 72 80 3294 3302 O
AND 81 84 3303 3306 O
have 85 89 3307 3311 O
a 90 91 3312 3313 O
resistant 92 101 3314 3323 O
genotype 102 110 3324 3332 O

enrolled 0 8 3333 3341 O
at 9 11 3342 3344 O
collection 12 22 3345 3355 O
of 23 25 3356 3358 O
at 26 28 3359 3361 O
least 29 34 3362 3367 O
3.0 35 38 3368 3371 B-lower_bound
x 39 40 3372 3373 I-lower_bound
10 41 43 3374 3376 I-lower_bound
^ 43 44 3376 3377 I-lower_bound
6 44 45 3377 3378 I-lower_bound
CD34 46 50 3379 3383 I-lower_bound
cells 51 56 3384 3389 I-lower_bound
/ 56 57 3389 3390 I-lower_bound
kg 57 59 3390 3392 I-lower_bound
of 60 62 3393 3395 O
autologous 63 73 3396 3406 B-clinical_variable
hematopoietic 74 87 3407 3420 I-clinical_variable
progenitor 88 98 3421 3431 I-clinical_variable
cells 99 104 3432 3437 I-clinical_variable
( 105 106 3438 3439 I-clinical_variable
HPC 106 109 3439 3442 I-clinical_variable
- 109 110 3442 3443 I-clinical_variable
A 110 111 3443 3444 I-clinical_variable
) 111 112 3444 3445 I-clinical_variable
by 113 115 3446 3448 O
apheresis 116 125 3449 3458 B-treatment
; 125 126 3458 3459 O
a 127 128 3460 3461 O
minimum 129 136 3462 3469 O
of 137 139 3470 3472 O
2 140 141 3473 3474 B-lower_bound
collection 142 152 3475 3485 O
procedures 153 163 3486 3496 O
is 164 166 3497 3499 O
required 167 175 3500 3508 O
, 175 176 3508 3509 O
unless 177 183 3510 3516 O
collection 184 194 3517 3527 O
on 195 197 3528 3530 O
day 198 201 3531 3534 O
# 202 203 3535 3536 O
1 204 205 3537 3538 O
> 206 207 3539 3540 O
5.0 208 211 3541 3544 B-lower_bound
x 212 213 3545 3546 I-lower_bound
10 214 216 3547 3549 I-lower_bound
^ 216 217 3549 3550 I-lower_bound
6 217 218 3550 3551 I-lower_bound
, 218 219 3551 3552 I-lower_bound
CD34 220 224 3553 3557 I-lower_bound
cells 225 230 3558 3563 I-lower_bound
/ 230 231 3563 3564 I-lower_bound
kg 231 233 3564 3566 I-lower_bound
; 233 234 3566 3567 O
a 235 236 3568 3569 O
maximum 237 244 3570 3577 O
of 245 247 3578 3580 O
10 248 250 3581 3583 O
collections 251 262 3584 3595 O
is 263 265 3596 3598 O
allowed 266 273 3599 3606 O

may 0 3 3607 3610 O
not 4 7 3611 3614 O
be 8 10 3615 3617 O
receiving 11 20 3618 3627 O
any 21 24 3628 3631 O
other 25 30 3632 3637 O
investigational 31 46 3638 3653 B-treatment
agents 47 53 3654 3660 I-treatment
, 53 54 3660 3661 O
or 55 57 3662 3664 O
concurrent 58 68 3665 3675 O
biological 69 79 3676 3686 B-treatment
, 79 80 3686 3687 O
chemotherapy 81 93 3688 3700 B-treatment
, 93 94 3700 3701 O
or 95 97 3702 3704 O
radiation 98 107 3705 3714 B-treatment
therapy 108 115 3715 3722 I-treatment
; 115 116 3722 3723 O
may 117 120 3724 3727 O
have 121 125 3728 3732 O
received 126 134 3733 3741 O
an 135 137 3742 3744 O
experimental 138 150 3745 3757 B-treatment
agent 151 156 3758 3763 I-treatment
prior 157 162 3764 3769 O
to 163 165 3770 3772 O
enrolling 166 175 3773 3782 O
in 176 178 3783 3785 O
the 179 182 3786 3789 O
trial 183 188 3790 3795 O

pathologically 0 14 3796 3810 O
confirmed 15 24 3811 3820 O
diagnosis 25 34 3821 3830 O
of 35 37 3831 3833 O
systemic 38 46 3834 3842 O
mature 47 53 3843 3849 O
T 54 55 3850 3851 B-cancer
- 55 56 3851 3852 I-cancer
cell 56 60 3852 3856 I-cancer
non 61 64 3857 3860 I-cancer
- 64 65 3860 3861 I-cancer
Hodgkin 65 72 3861 3868 I-cancer
lymphoma 73 81 3869 3877 I-cancer
( 82 83 3878 3879 I-cancer
NHL 83 86 3879 3882 I-cancer
) 86 87 3882 3883 I-cancer
with 88 92 3884 3888 O
City 93 97 3889 3893 O
of 98 100 3894 3896 O
Hope 101 105 3897 3901 O
pathology 106 115 3902 3911 O
review 116 122 3912 3918 O
as 123 125 3919 3921 O
per 126 129 3922 3925 O
World 130 135 3926 3931 O
Health 136 142 3932 3938 O
Organization 143 155 3939 3951 O
( 156 157 3952 3953 O
WHO 157 160 3953 3956 O
) 160 161 3956 3957 O
classification 162 176 3958 3972 O
of 177 179 3973 3975 O
lymphomas 180 189 3976 3985 B-cancer
2008 190 194 3986 3990 O
, 194 195 3990 3991 O
who 196 199 3992 3995 O
are 200 203 3996 3999 O
deemed 204 210 4000 4006 O
eligible 211 219 4007 4015 O
for 220 223 4016 4019 O
high 224 228 4020 4024 B-treatment
dose 229 233 4025 4029 I-treatment
therapy 234 241 4030 4037 I-treatment
and 242 245 4038 4041 O
AHCT 246 250 4042 4046 B-treatment

psychosocial 0 12 4047 4059 B-chronic_disease
circumstances 13 26 4060 4073 I-chronic_disease
or 27 29 4074 4076 I-chronic_disease
illnesses 30 39 4077 4086 I-chronic_disease
that 40 44 4087 4091 O
preclude 45 53 4092 4100 O
protocol 54 62 4101 4109 O
participation 63 76 4110 4123 O
( 77 78 4124 4125 O
to 78 80 4125 4127 O
be 81 83 4128 4130 O
determined 84 94 4131 4141 O
by 95 97 4142 4144 O
P.I. 98 102 4145 4149 O
) 102 103 4149 4150 O

should 0 6 4151 4157 O
not 7 10 4158 4161 O
have 11 15 4162 4166 O
any 16 19 4167 4170 O
uncontrolled 20 32 4171 4183 O
illness 33 40 4184 4191 O
including 41 50 4192 4201 O
ongoing 51 58 4202 4209 O
or 59 61 4210 4212 O
active 62 68 4213 4219 B-chronic_disease
infection 69 78 4220 4229 I-chronic_disease
requiring 79 88 4230 4239 O
therapy 89 96 4240 4247 B-treatment

